from web site

The FDA will continue to help with the schedule of safe and reliable digital health gadgets that might enhance client access to needed healthcare." The device, called IDx-DR, is a software program that uses an expert system algorithm to analyze pictures of the eye taken with a retinal electronic camera called the Topcon NW400.
If the images are of sufficient quality, the software offers the medical professional with one of 2 results: (1) "more than mild diabetic retinopathy detected: describe an eye care professional" or (2) "unfavorable for more than moderate diabetic retinopathy; rescreen in 12 months." If a favorable outcome is spotted, patients must see an eye care service provider for further diagnostic evaluation and possible treatment as soon as possible.
The FDA examined data from a scientific study of retinal images acquired from 900 patients with diabetes at 10 medical care websites. The study was developed to assess how typically IDx-DR might precisely find clients with more than mild diabetic retinopathy. In visit the site , IDx-DR had the ability to properly determine the presence of more than moderate diabetic retinopathy 87.


5 percent of the time. Clients who have a history of laser treatment, surgery or injections in the eye or who have any of the list below conditions ought to not be screened for diabetic retinopathy with IDx-DR: persistent vision loss, blurred vision, floaters, previously diagnosed macular edema, serious non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy or retinal vein occlusion.
IDx-DR is only designed to spot diabetic retinopathy, including macular edema; it must not be utilized to detect any other illness or condition. Patients will still need to get a total eye examination at the age of 40 and at the age of 60 and likewise if they have any vision symptoms (for example, consistent vision loss, blurred vision or floaters).